EA
CRL icon

Everpar Advisors’s Charles River Laboratories CRL Stock Holding History

Everpar Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,832
Closed -$276K – 269
2025
Q1 		$276K Sell
1,832
-114
-6% -$19.1K 0.15% 200
2024
Q4 		$359K Sell
1,946
-7
-0.4% -$1.35K 0.18% 152
2024
Q3 		$385K Sell
1,953
-394
-17% -$81.9K 0.2% 152
2024
Q2 		$485K Buy
2,347
+36
+2% +$8.16K 0.24% 123
2024
Q1 		$626K Sell
2,311
-1,573
-40% -$376K 0.38% 75
2023
Q4 		$918K Buy
+3,884
New +$764K 0.43% 70

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Everpar Advisors's CRL Position: Q2 2025 in Review

Everpar Advisors sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 1,832 shares — an estimated $276K sold.

Everpar Advisors first reported a position in CRL in Q4 2023 and held it in 6 quarters. The position peaked at $918K in Q4 2023. 518 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

  • Everpar Advisors reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
  • Everpar Advisors sold 1,832 Charles River Laboratories shares in Q2 2025, an estimated $276K.
  • Everpar Advisors first reported a position in Charles River Laboratories in Q4 2023 and held it in 6 quarters.
  • Everpar Advisors's Charles River Laboratories position peaked at $918K in Q4 2023.
  • 518 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on Everpar Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.